• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BioNTech SE - American Depositary Shares (NQ:BNTX)

    103.91 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about BioNTech SE - American Depositary Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    70 71 Next >
    BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
    From BioNTech SE
    Via GlobeNewswire
    New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
    EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Unveiling 12 Analyst Insights On BioNTech
     
    Via Benzinga
    New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
    From FN Media Group LLC
    Via GlobeNewswire
    UK, Taiwan Approve Moderna's Updated COVID-19 Shot
    The Medicines and Healthcare Products Regulatory Agency has approved Moderna's updated COVID-19 vaccine targeting the JN.1 variant, available for eligible groups through the NHS autumn program and for... 
    Via Benzinga
    Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million
    UCB announced plans to divest its current China five-drug portfolio, narrowing its China focus to commercialize soon-to-arrive late-stage clinical assets. It will sell this “mature” neurology and... 
    Via Talk Markets
    Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
    BioNTech and Moderna are advancing personalized cancer vaccines using mRNA technology. Despite promising early results, these innovative treatments face challenges in cost, scalability, and... 
    Via Benzinga
    Americans To Access COVID-19 Test Kits For Free As US Government Restarts Free At-Home Program
    US households can order free COVID-19 tests starting in late September as the government reopens the program ahead of the fall virus season. 
    Via Benzinga
    FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot
    The FDA granted emergency use authorization for updated mRNA COVID-19 vaccines targeting the Omicron KP.2 strain, including new formulas from Moderna and Pfizer/BioNTech. These vaccines, designed to... 
    Via Benzinga
    Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
    From Pfizer Inc.
    Via Business Wire
    Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
    From BioNTech SE
    Via GlobeNewswire
    FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
    The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak. 
    Via Benzinga
    Topics ETFs
    Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
    Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release. 
    Via MarketBeat
    FDA Allows Resumption Of BioNTech/MediLink Therapeutics Partnered Phase 1 Study For Cancer Drug With Lower Dose
    FDA lifts partial hold on MediLink Therapeutics' phase 1 trial for HER3-targeting ADC BNT326/YL202 in advanced lung and breast cancer patients; trial resumes with revised dose limits following safety... 
    Via Benzinga
    Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
    A clinical-trial failure for Pfizer and BioNTech means Moderna is leading the race to develop a combo shot for the flu and COVID-19. 
    Via The Motley Fool
    Why Pfizer Stock Slumped on Friday
    Investors were cautiously pessimistic about the latest news coming out of the company's lab. 
    Via The Motley Fool
    Pfizer Slides Toward Sell Zone After BioNTech-Tied Covid/Flu Shot Misses Its Mark
    The company is now considering whether it needs to change up the vaccine to pass muster. 
    Via Investor's Business Daily
    Pfizer, BioNTech's COVID-19/Flu Combo Vaccine Fails To Meet Key Goal In Late-Stage Study
    Pfizer and BioNTech report Phase 3 results for their combined mRNA vaccine against influenza and COVID-19. The trial met one of two primary immunogenicity objectives. Adjustments are planned to improve... 
    Via Benzinga
    Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
    From Pfizer Inc.
    Via Business Wire
    Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
    From BioNTech SE
    Via GlobeNewswire
    Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows
    COVID-19 vaccinations could lower the incidence of heart attacks and strokes, according to a new study by UK universities. The research shows a significant reduction in cardiovascular events among... 
    Via Benzinga
    Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
    A recent NIH study reveals no clear diagnostic test for Long Covid, highlighting ongoing challenges in identifying and treating the condition affecting millions of Americans. Researchers continue to... 
    Via Benzinga
    Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
    Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases. 
    Via MarketBeat
    3 Biotech Stocks With Promising Drug Pipelines: August 2024
    The biotech stocks with promising pipelines could see shares soar if drugs in late-stage trials get FDA approval. 
    Via InvestorPlace
    This Cognizant Technology Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
     
    Via Benzinga
    BioNTech Se (BNTX) Q2 2024 Earnings Call Transcript
    BNTX earnings call for the period ending June 30, 2024. 
    Via The Motley Fool
    Topics Earnings
    US Stocks Trim Black Monday's Drops As Services Gauge Expands, Bond Gains Stall As Traders Reassess Fed Cuts: What's Driving Markets Monday?
    Global markets are experiencing intense volatility, and while it seemed like a Black Monday for Wall Street was inevitable following a 13% overnight tumble of Japan’s Nikkei 225, stock indices are... 
    Via Benzinga
    Topics Economy
    Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
    Moderna sustained a rare downgrade on Monday following its guidance cut for the year. 
    Via Investor's Business Daily
    BNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q2 2024
    BNTX stock results show that BioNTech missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
    BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID-19 vaccines shifted. R&D expenses rose due to late-stage oncology... 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    70 71 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.